Net Income (Loss) Attributable to Parent in USD of RELMADA THERAPEUTICS, INC. from 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Relmada Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from 2010 to Q3 2025.
  • Relmada Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$10.1M, a 53.6% increase year-over-year.
  • Relmada Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$56.2M, a 35% increase year-over-year.
  • Relmada Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$80M, a 19% increase from 2023.
  • Relmada Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$98.8M, a 37.1% increase from 2022.
  • Relmada Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$157M, a 24.9% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

RELMADA THERAPEUTICS, INC. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$56.2M -$10.1M +$11.6M +53.6% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025
Q2 2025 -$67.8M -$9.87M +$7.9M +44.5% 01 Apr 2025 30 Jun 2025 10-Q 13 Nov 2025
Q1 2025 -$75.7M -$17.6M +$4.27M +19.6% 01 Jan 2025 31 Mar 2025 10-Q 13 Nov 2025
Q4 2024 -$80M -$18.7M +$6.51M +25.9% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025
Q3 2024 -$86.5M -$21.7M +$276K +1.26% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025
Q2 2024 -$86.8M -$17.8M +$7.53M +29.8% 01 Apr 2024 30 Jun 2024 10-Q 13 Nov 2025
Q1 2024 -$94.3M -$21.8M +$4.49M +17.1% 01 Jan 2024 31 Mar 2024 10-Q 13 Nov 2025
Q4 2023 -$98.8M -$25.2M +$12.8M +33.7% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025
Q3 2023 -$112M -$22M +$17.4M +44.2% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024
Q2 2023 -$129M -$25.3M +$14.6M +36.6% 01 Apr 2023 30 Jun 2023 10-Q 07 Nov 2024
Q1 2023 -$144M -$26.3M +$13.4M +33.8% 01 Jan 2023 31 Mar 2023 10-Q 07 Nov 2024
Q4 2022 -$157M -$37.9M -$3.57M -10.4% 01 Oct 2022 31 Dec 2022 10-K 19 Mar 2024
Q3 2022 -$153M -$39.4M +$3.19M +7.48% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023
Q2 2022 -$157M -$39.9M -$13.4M -50.4% 01 Apr 2022 30 Jun 2022 10-Q 08 Nov 2023
Q1 2022 -$143M -$39.7M -$17.5M -78.9% 01 Jan 2022 31 Mar 2022 10-Q 08 Nov 2023
Q4 2021 -$126M -$34.4M -$13.6M -65.6% 01 Oct 2021 31 Dec 2021 10-K 23 Mar 2023
Q3 2021 -$112M -$42.6M -$25.7M -152% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022
Q2 2021 -$86.4M -$26.6M -$15.4M -139% 01 Apr 2021 30 Jun 2021 10-Q 10 Nov 2022
Q1 2021 -$71M -$22.2M -$11.5M -108% 01 Jan 2021 31 Mar 2021 10-Q 10 Nov 2022
Q4 2020 -$59.5M -$20.8M -$16.2M -359% 01 Oct 2020 31 Dec 2020 10-K 25 Mar 2022
Q3 2020 -$43.2M -$16.9M -$13.2M -361% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021
Q2 2020 -$30M -$11.1M -$7M -170% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021
Q1 2020 -$23M -$10.7M -$7.99M -297% 01 Jan 2020 31 Mar 2020 10-Q 12 May 2021
Q4 2019 -$15M -$4.53M +$2.6M +36.5% 01 Oct 2019 31 Dec 2019 10-K 24 Mar 2021
Q3 2019 -$17.6M -$3.67M -$289K -8.56% 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020
Q2 2019 -$17.3M -$4.12M -$773K -23.1% 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2020
Q1 2019 -$16.5M -$2.69M +$516K +16.1% 01 Jan 2019 31 Mar 2019 10-Q 12 Aug 2020
Q4 2018 -$17.1M -$7.13M -$5.7M -399% 01 Oct 2018 31 Dec 2018 10-Q 15 May 2019
Q3 2018 -$11.4M -$3.38M -$2.4M -244% 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2019
Q2 2018 -$8.96M -$3.35M -$1.72M -105% 01 Apr 2018 30 Jun 2018 10-KT 26 Mar 2020
Q1 2018 -$7.24M -$3.2M -$1.22M -61.6% 01 Jan 2018 31 Mar 2018 10-Q 15 May 2019
Q4 2017 -$6.02M -$1.43M -$397K -38.5% 01 Oct 2017 31 Dec 2017 10-Q 15 May 2019
Q3 2017 -$5.63M -$982K +$659K +40.2% 01 Jul 2017 30 Sep 2017 10-Q 15 May 2019
Q2 2017 -$6.29M -$1.63M +$1.68M +50.8% 01 Apr 2017 30 Jun 2017 10-K 28 Sep 2018
Q1 2017 -$7.97M -$1.98M -$122K -6.55% 01 Jan 2017 31 Mar 2017 10-Q 14 May 2018
Q4 2016 -$7.85M -$1.03M +$1.43M +58.1% 01 Oct 2016 31 Dec 2016 10-Q 12 Feb 2018
Q3 2016 -$9.28M -$1.64M -$6.3M -135% 01 Jul 2016 30 Sep 2016 10-Q 14 Nov 2017
Q2 2016 -$2.97M -$3.32M -$9.36M -155% 01 Apr 2016 30 Jun 2016 10-K 28 Sep 2017
Q1 2016 $6.39M -$1.86M +$603K +24.5% 01 Jan 2016 31 Mar 2016 10-Q 15 May 2017
Q4 2015 $5.78M -$2.46M -$7.92M -145% 01 Oct 2015 31 Dec 2015 10-Q 10 Feb 2017
Q3 2015 $13.7M $4.66M +$34.5M 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016
Q2 2015 -$20.8M $6.04M 01 Apr 2015 30 Jun 2015 10-K 09 Sep 2016
Q1 2015 -$2.46M -$8.96M -138% 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016
Q4 2014 $5.46M +$10.6M 01 Oct 2014 31 Dec 2014 10-Q 05 Feb 2016
Q3 2014 -$29.8M -$28.3M -1806% 01 Jul 2014 30 Sep 2014 10-Q 06 Nov 2015
Q1 2014 $6.49M +$7.12M 01 Jan 2014 31 Mar 2014 10-Q 15 May 2015
Q4 2013 -$5.17M -$5.16M 01 Oct 2013 31 Dec 2013 10-Q 13 Feb 2015
Q3 2013 -$1.57M 01 Jul 2013 30 Sep 2013 10-Q 07 Nov 2014
Q1 2013 -$630K 01 Jan 2013 31 Mar 2013 8-K 27 May 2014
Q4 2012 -$9.02K* 01 Sep 2012 30 Nov 2012 10-Q 13 Jan 2014
Q3 2011 -$90* 23 May 2011 31 Aug 2011 10-K 16 Dec 2013

RELMADA THERAPEUTICS, INC. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$80M +$18.8M +19% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025
2023 -$98.8M +$58.3M +37.1% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025
2022 -$157M -$31.3M -24.9% 01 Jan 2022 31 Dec 2022 10-K 19 Mar 2024
2021 -$126M -$66.3M -112% 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023
2020 -$59.5M -$44.5M -296% 01 Jan 2020 31 Dec 2020 10-K 25 Mar 2022
2019 -$15M -$6.04M -67.5% 01 Jan 2019 31 Dec 2019 10-K 24 Mar 2021
2018 -$8.96M -$2.67M -42.5% 01 Jul 2017 30 Jun 2018 10-KT 26 Mar 2020
2017 -$6.29M -$3.31M -111% 01 Jul 2016 30 Jun 2017 10-K 28 Sep 2018
2016 -$2.97M +$17.8M +85.7% 01 Jul 2015 30 Jun 2016 10-K 28 Sep 2017
2015 -$20.8M 01 Jul 2014 30 Jun 2015 10-K 09 Sep 2016
2013 -$19.9M -$13M -190% 01 Jan 2013 31 Dec 2013 10-K 11 Sep 2015
2012 -$6.86M -$5.99M -685% 01 Jan 2012 31 Dec 2012 10-KT 09 Sep 2014
2011 -$874K -$43K -5.18% 01 Jan 2011 31 Dec 2011 8-K 27 May 2014
2010 -$831K 01 Jan 2010 31 Dec 2010 8-K 27 May 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.